tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SE:HNSA Stock Latest News

Hansa Biopharma Expands Share Capital with New Share Issue
Company AnnouncementsHansa Biopharma Expands Share Capital with New Share Issue
1h ago
Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial
PremiumCompany Announcements
Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial
1d ago
Hansa Biopharma Hosts Event on Imlifidase Phase 3 Results
PremiumCompany Announcements
Hansa Biopharma Hosts Event on Imlifidase Phase 3 Results
2d ago
Hansa Biopharma’s Imlifidase Study: A Potential Game-Changer in Kidney Transplantation
PremiumCompany Announcements
Hansa Biopharma’s Imlifidase Study: A Potential Game-Changer in Kidney Transplantation
4d ago
HNSA
Sarepta and Hansa’s Gene Therapy Study: A Potential Breakthrough for DMD Treatment
PremiumCompany Announcements
Sarepta and Hansa’s Gene Therapy Study: A Potential Breakthrough for DMD Treatment
4d ago
SRPT
Hansa Biopharma’s Imlifidase Study: A Potential Game-Changer in Kidney Transplantation
PremiumCompany AnnouncementsHansa Biopharma’s Imlifidase Study: A Potential Game-Changer in Kidney Transplantation
4d ago
HNSA
Hansa Biopharma’s Imlifidase Study: A Potential Game-Changer for Pediatric Kidney Transplants
Premium
Company Announcements
Hansa Biopharma’s Imlifidase Study: A Potential Game-Changer for Pediatric Kidney Transplants
4d ago
HNSA
Hansa Biopharma’s Imlifidase: A Promising Catalyst for AAV-Based Gene Therapy Expansion
Premium
Ratings
Hansa Biopharma’s Imlifidase: A Promising Catalyst for AAV-Based Gene Therapy Expansion
21d ago
Hansa Biopharma’s Imlifidase Enables Breakthrough in Gene Therapy for Crigler-Najjar Syndrome
PremiumCompany Announcements
Hansa Biopharma’s Imlifidase Enables Breakthrough in Gene Therapy for Crigler-Najjar Syndrome
21d ago
Hansa Biopharma to Discuss Q3 2025 Results in Upcoming Conference Call
PremiumCompany Announcements
Hansa Biopharma to Discuss Q3 2025 Results in Upcoming Conference Call
23d ago
Hansa Biopharma CEO to Participate in Key Industry Conferences
PremiumCompany Announcements
Hansa Biopharma CEO to Participate in Key Industry Conferences
24d ago
Hansa Biopharma Announces Directed Share Issue for Nasdaq Stockholm Trading
PremiumCompany Announcements
Hansa Biopharma Announces Directed Share Issue for Nasdaq Stockholm Trading
29d ago
Hansa Biopharma Raises USD 71 Million to Boost U.S. Market Efforts
PremiumCompany AnnouncementsHansa Biopharma Raises USD 71 Million to Boost U.S. Market Efforts
30d ago
Hansa Biopharma Plans USD 60 Million Share Issue to Boost U.S. Market Efforts
Premium
Company Announcements
Hansa Biopharma Plans USD 60 Million Share Issue to Boost U.S. Market Efforts
30d ago
Hansa Biopharma’s Imlifidase Shows Promise in Gene Therapy for Crigler-Najjar Syndrome
Premium
Company Announcements
Hansa Biopharma’s Imlifidase Shows Promise in Gene Therapy for Crigler-Najjar Syndrome
1M ago
Hansa Biopharma AB: Buy Rating Affirmed on Positive Phase 3 Trial Results for Imlifidase
PremiumRatings
Hansa Biopharma AB: Buy Rating Affirmed on Positive Phase 3 Trial Results for Imlifidase
1M ago
Hansa Biopharma Reports Positive Phase 3 Trial Results for Imlifidase in Kidney Transplantation
PremiumCompany Announcements
Hansa Biopharma Reports Positive Phase 3 Trial Results for Imlifidase in Kidney Transplantation
1M ago
Hansa Biopharma to Present at Pareto Healthcare Conference
PremiumCompany Announcements
Hansa Biopharma to Present at Pareto Healthcare Conference
2M ago
Hansa Biopharma to Engage at Global Investment Conference
PremiumCompany Announcements
Hansa Biopharma to Engage at Global Investment Conference
2M ago
Hansa Biopharma Announces New Board Members at Extraordinary General Meeting
PremiumCompany AnnouncementsHansa Biopharma Announces New Board Members at Extraordinary General Meeting
2M ago
Hansa Biopharma Announces Extraordinary General Meeting for Board Elections
Premium
Company Announcements
Hansa Biopharma Announces Extraordinary General Meeting for Board Elections
3M ago
Hansa Biopharma AB: Promising Growth in Gene Therapy with Imlifidase Breakthrough
Premium
Ratings
Hansa Biopharma AB: Promising Growth in Gene Therapy with Imlifidase Breakthrough
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >